[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639508":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":75,"collaborators":24,"id":77,"slug":24,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":24,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":24,"enrollmentInfo":85,"targetDuration":24,"studyType":88,"phases":89,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"United Immunity, co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"UI-102 Monotherapy, IV infusion","EXPERIMENTAL","UI-102 monotherapy administered intravenously. This arm includes Phase I dose escalation, backfill cohorts, and cohort expansion in participants with selected locally advanced and\u002For metastatic solid tumors.",[13],"Drug: UI-102",{"label":15,"type":10,"description":16,"interventionNames":17},"UI-102 Combination Therapy, IV infusion","UI-102 administered intravenously in combination with standard-of-care agents commonly used. This arm includes dose escalation, dose optimization, and cohort expansion.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","UI-102","Specified dose on specified days",[15,9],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"K Hashimoto, MD","CONTACT","+81 (0)3-6265-1670","clinical-contact@unitedimmunity.co.jp",[32,51,63],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"NEXT Oncology","RECRUITING","Dallas","Texas","75039","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-96.80667,32.78306,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":49,"phoneExt":24,"email":50},"Clinical Trial Navigator","972-893-8800","fakinwale@nextoncology.com",{"facility":33,"status":34,"city":52,"state":36,"zip":53,"country":38,"countryCode":39,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Houston","77054",{"type":41,"coordinates":55},[56,57],-95.36327,29.76328,{"lat":57,"lon":56},[60],{"name":48,"role":28,"phone":61,"phoneExt":24,"email":62},"832-384-7912","emorales@nextoncology.com",{"facility":33,"status":34,"city":64,"state":36,"zip":65,"country":38,"countryCode":39,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"San Antonio","78229",{"type":41,"coordinates":67},[68,69],-98.49363,29.42412,{"lat":69,"lon":68},[72],{"name":48,"role":28,"phone":73,"phoneExt":24,"email":74},"210-580-9521","jgeorg@nextoncology.com",{"type":76,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100639508",false,"NCT07605962","Phase 1\u002F2 Study of UI-102 in Selected Advanced Cancers","A Phase I\u002FII Open-Label, Dose Escalation, Dose Optimization, and Cohort Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of UI-102, a Novel Cholesteryl Pullulan (CHP) Nanoparticle-formulated TLR7\u002F8 Agonist in Patients With Selected Locally Advanced and\u002For Metastatic Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1,\n* 18 Years and Older (adult, older adult),\n* Histologically confirmed advanced cancer,\n* Archived or fresh tumor tissue sample that must be confirmed as adequate,\n* Evaluable\u002FMeasurable disease per RECIST 1.1,\n* Previously received applicable standard treatments,\n* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control\n\nExclusion Criteria:\n\n* central nervous system metastasis,\n* Ongoing or uncontrolled ascites or pleural effusion,\n* Significant ongoing toxicity from prior anticancer treatment,\n* Out-of-range laboratory values,\n* Clinically significant lung, heart, or autoimmune disease,\n* Ongoing requirement for immunosuppressive treatment,\n* Significant secondary malignancy,\n* Hypersensitivity to study drug or excipients,\n* Pregnant or lactating,\n* Ongoing active infection","ALL","18 Years",{"count":86,"type":87},140,"ESTIMATED","INTERVENTIONAL",[90,91],"PHASE1","PHASE2","This phase 1\u002F2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7\u002F8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.",[94],"Advanced Cancer",[96,97],"metastatic solid tumors","advanced solid tumors","2026-06-01",{"date":100,"type":101},"2026-06-03","ACTUAL",{"date":103,"type":101},"2026-05-20",{"date":105,"type":87},"2031-03-31",{"name":5,"class":6},3]